AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7608322
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration (5 mg)
Trial: 7608322
Drug: Inhaled administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled administration (2 mg)
Trial: 7608322
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (Intravenous, Oral, Inhaled)
Trial: 323443
Drug: Naloxone, 0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone, 0.01 mg/kg intramuscularly
Trial: 17335317
Drug: Topiramate (started
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate (started at 25 mg/day, titrated to 400 mg/day or maximum tolerated dose)
Trial: 6762370
Drug: L‐carnitine (1.2‐1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐carnitine (1.2‐1.8 g/day)
Trial: 31362119
Drug: Double negative
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double negative for HBV DNA and RNA at the end of treatment (evaluation cohort)
Trial: 31362119
Drug: Positive for
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive for either HBV DNA or RNA at the end of treatment (evaluation cohort)
Trial: 31362119
Drug: Double negative
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double negative for HBV DNA and RNA at the end of treatment (validation cohort)
Trial: 31362119
Drug: Positive for
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive for either HBV DNA or RNA at the end of treatment (validation cohort)
Trial: 28342061
Drug: Obinutuzumab in
RxNorm normalized name: obinutuzumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obinutuzumab in combination with chlorambucil (GClb)
Trial: 28342061
Drug: Rituximab in
RxNorm normalized name: rituximab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab in combination with chlorambucil (RClb)
Trial: 27423373
Drug: Enhanced cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced cognitive behavioural therapy (CBT‐E)
Trial: 27423373
Drug: Enhanced cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced cognitive behavioural therapy (CBT‐E) and Interpersonal psychotherapy (IPT)
Trial: 22818904
Drug: Half-dose verteporfin
RxNorm normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Half-dose verteporfin photodynamic therapy (PDT)
Trial: 15800144
Drug: PROSPECT intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PROSPECT intervention (care management model with trained care managers providing algorithm-based recommendations and treatment adherence support over 18 months)
Trial: 10559522
Drug: 375 ml
RxNorm normalized name: isopropyl alcohol 0.0375 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 375 ml of red wine (30 g alcohol) per day for 2 weeks
Trial: 7505360
Drug: Losartan (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (20 mg)
Trial: 28607125
Drug: Enalapril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (10 mg)
Trial: 21744761
Drug: Lidocaine 2.0%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 2.0% (intravenous bolus 1.5 mg/kg followed by an infusion of 1.5 mg/kg/h)
Trial: 15953979
Drug: Minimal intervention
RxNorm normalized name: Centipeda minima whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal intervention (verbal information on the Medicaid pharmacotherapy benefit)
Trial: 7272163
Drug: Caroxazone 300
RxNorm normalized name: Caroxazone
DrugBank: Caroxazone (DB09254)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caroxazone 300 mg/day for 12 days
Trial: 7272163
Drug: Caroxazone 600
RxNorm normalized name: Caroxazone
DrugBank: Caroxazone (DB09254)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caroxazone 600 mg/day for 12 days
Trial: 7272163
Drug: Tranylcypromine 20
RxNorm normalized name: tranylcypromine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tranylcypromine 20 mg/day for 8 days
Trial: 7272163
Drug: Imipramine 50
RxNorm normalized name: trimipramine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine 50 mg/day for 12 days
Trial: 7272163
Drug: Caroxazone 300
RxNorm normalized name: Caroxazone
DrugBank: Caroxazone (DB09254)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caroxazone 300 mg/day
Trial: 7272163
Drug: Caroxazone 600
RxNorm normalized name: Caroxazone
DrugBank: Caroxazone (DB09254)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caroxazone 600 mg/day
Trial: 30391759
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of Tranexamic Acid (TXA)
Trial: 30391759
Drug: Topical administration
RxNorm normalized name: Octocaine 5 % Ointment for Oral and Topical Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical administration of Tranexamic Acid (TXA)
Trial: 28200045
Drug: Single-dose regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose regimen of Benzathine Penicillin G (2.4 million units)
Trial: 28200045
Drug: 3-dose regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-dose regimen of Benzathine Penicillin G
Trial: 25389044
Drug: Patent Blue
RxNorm normalized name: Patent Blue
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patent Blue dye injection
Trial: 16918888
Drug: Famotidine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine (40 mg/day)
Trial: 11176963
Drug: ABT-431 (5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-431 (5, 10, 20, and 40 mg)
Trial: 7915067
Drug: Esmolol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol (0.5 mg/kg/1 min bolus, followed by 0.2 mg/kg/min infusion)
Trial: 7915067
Drug: Gallopamil (0.025
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gallopamil (0.025 mg/kg/3 min)
Trial: 2968052
Drug: alpha-hANP infusion
RxNorm normalized name: One-Alpha
DrugBank: Alfacalcidol (DB01436)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha-hANP infusion at 10 pmol.kg‐1.min‐1 for 1 hour
Trial: 2968052
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion (vehicle)
Trial: 2968052
Drug: alpha-hANP infusion
RxNorm normalized name: One-Alpha
DrugBank: Alfacalcidol (DB01436)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha-hANP infusion
Trial: 2968052
Drug: alpha-hANP infusion
RxNorm normalized name: One-Alpha
DrugBank: Alfacalcidol (DB01436)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha-hANP infusion in normal volunteers
Trial: 24074932
Drug: Passively scattered
RxNorm normalized name: RESPIRATORY TUBE 22MM PASSIVE R#1147378
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Passively scattered proton therapy (PSPT)
Trial: 24074932
Drug: Intensity modulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensity modulated photon therapy (IMRT)
Trial: 20675936
Drug: Amino-bisphosphonate treatment
RxNorm normalized name: (4-amino-1-hydroxybutylidene)bisphosphonic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino-bisphosphonate treatment for Osteogenesis Imperfecta
Trial: 12667386
Drug: Oseltamivir phosphate,
RxNorm normalized name: Oseltamivir Phosphate, 75 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir phosphate, 75 mg twice daily for 5 days
Trial: 7408415
Drug: Heparin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (50 U intravenously)
Trial: 7408415
Drug: Cumulative doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cumulative doses of heparin
Trial: 7408415
Drug: Heparin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (400 U intravenously of Harris LO14)
Trial: 7408415
Drug: Heparin (small
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (small doses)
Trial: 31495331
Drug: Intravenous allogeneic
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous allogeneic mesenchymal stem cells (1.5 million cells/kg body weight)
Trial: 17729010
Drug: Intravenous anticoagulation
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous anticoagulation using i.v. heparin infusion
Trial: 15132725
Drug: Budesonide 200
RxNorm normalized name: budesonide 200 mcg/inh inhalation powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 200 microg/day (low dose group)
Trial: 15132725
Drug: Budesonide 800
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide 800 microg/day (high dose group)
Trial: 11463679
Drug: Brief psychodynamic
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief psychodynamic interpersonal therapy
Trial: 7739439
Drug: Antibiotic added
RxNorm normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotic added to sterile physiologic solution
Trial: 7739439
Drug: Through drainage
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA spike protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Through drainage with sterile physiologic solution
Trial: 2918157
Drug: Intravenous diltiazem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous diltiazem (0.25 mg/kg followed by 0.35 mg/kg body weight)
Trial: 163386
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid (1 gm three times a day for nine months, plus 3 gm daily at onset of cold)
Trial: 25936298
Drug: 500 ml
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 ml whipping cream (30% fat)
Trial: 25936298
Drug: 0.1 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 g/kg l‐methionine
Trial: 17509903
Drug: Nitric oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitric oxide donation via a patch
Trial: 15350490
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with 3 million units (MU) of alpha‐interferon and 200 mg of ribavirin three times a week for 24 weeks.
Trial: 15350490
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with 3 million units (MU) of alpha‐interferon and 200 mg of ribavirin three times a week for 48 weeks.
Trial: 9738086
Drug: Lorazepam (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (0.1 mg per kilogram)
Trial: 9738086
Drug: Phenobarbital (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenobarbital (15 mg per kilogram)
Trial: 9738086
Drug: Diazepam (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (0.15 mg per kilogram) followed by Phenytoin (18 mg per kilogram)
Trial: 9738086
Drug: Phenytoin (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenytoin (18 mg per kilogram)
Trial: 9738086
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (Lorazepam, Phenobarbital, Diazepam plus Phenytoin, Phenytoin)
Trial: 9304981
Drug: Traditional three-day
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional three-day bowel preparation
Trial: 4834974
Drug: Carbidopa plus
RxNorm normalized name: Carbidopa
DrugBank: Carbidopa (DB00190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbidopa plus 20% of previous levodopa dosage in fixed combination tablets (levodopa:carbidopa in a 10:1 ratio)
Trial: 4834974
Drug: Combination tablets
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination tablets (levodopa:carbidopa in a 10:1 ratio)
Trial: 22404184
Drug: Baclofen (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baclofen (40 mg)
Trial: 21654265
Drug: Febuxostat 40
RxNorm normalized name: febuxostat 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Febuxostat 40 mg/d
Trial: 21654268
Drug: Febuxostat 80
RxNorm normalized name: febuxostat 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Febuxostat 80 mg/d
Trial: 25120316
Drug: Febuxostat 120
RxNorm normalized name: Febuxostat 120 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Febuxostat 120 mg/d
Trial: 19464611
Drug: Fresh gas
RxNorm normalized name: Peroxi-Fresh
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fresh gas flow of 5 L/min
Trial: 19464611
Drug: Fresh gas
RxNorm normalized name: Peroxi-Fresh
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fresh gas flow of 10 L/min
Trial: 16239356
Drug: Ciprofloxacin ER
RxNorm normalized name: ciprofloxacin Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin ER (500 mg once daily)
Trial: 16239356
Drug: Ciprofloxacin IR
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin IR (250 mg twice daily)
Trial: 12219247
Drug: Slimming liposomes
RxNorm normalized name: arched swimming crab, cooked preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slimming liposomes (SLC) containing esculoside, Centella asiatica extracts, caffeine, and L-carnitine
Trial: 8749878
Drug: Digoxin with
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Digoxin with low-dose betaxolol (20 mg once daily)
Trial: 8749878
Drug: Digoxin with
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Digoxin with low-dose diltiazem (90 mg twice daily)
Trial: 8749878
Drug: Digoxin with
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Digoxin with low-dose diltiazem and digoxin with low-dose betaxolol
Trial: 18414916
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg morphine
Trial: 1098671
Drug: Teoremac (420
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teoremac (420 mg/day for 14 days)
Trial: 1098671
Drug: Indometacin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indometacin (100 mg/day for 14 days)
Trial: 31366226
Drug: Esketamine nasal
RxNorm normalized name: esketamine Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esketamine nasal spray combined with a newly initiated oral antidepressant
Trial: 15800157
Drug: Antidepressant plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant plus placebo
Trial: 25381345
Drug: Impairment-based approach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Impairment-based approach focusing on patients' generic abilities and activities of daily living (ADL).
Trial: 28640364
Drug: Axitinib (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axitinib (5 mg twice daily)
Trial: 16936557
Drug: GS-9137 (200,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GS-9137 (200, 400, or 800 mg BID, 800 mg QD, or 50 mg+100 mg ritonavir QD)
Trial: 14505546
Drug: Bifid Triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifid Triple Viable capsule (BIFICO), 420 mg/d
Trial: 26965429
Drug: Personalized e-therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized e-therapy program in addition to usual care
Trial: 17981067
Drug: DTPw‐HBV/Hib‐MenAC vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTPw‐HBV/Hib‐MenAC vaccine (2.5 microg of each polysaccharide, 5 microg of each polysaccharide, or 2.5 microg of PRP and 5 microg each of MenA and MenC)
Trial: 18478093
Drug: DTPw‐HBV/Hib‐MenAC vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTPw‐HBV/Hib‐MenAC vaccine
Trial: 17981067
Drug: Licensed DTPw‐HBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licensed DTPw‐HBV and Hib or DTPw‐HBV/Hib and MenC conjugate vaccines
Trial: 10751812
Drug: Pancuronium (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancuronium (0.1 mg kg(‐1))
Trial: 10751812
Drug: Pipecuronium (0.07
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pipecuronium (0.07 mg kg(‐1))
Trial: 2665352
Drug: ICRC vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICRC vaccine
Trial: 3965341
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A therapy, 50,000 U twice daily
Trial: 24703319
Drug: Non-bevacizumab treatment
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Non-bevacizumab treatment
Trial: 25712298
Drug: Acetazolamide 250
RxNorm normalized name: acetazolamide 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide 250 mg
Trial: 17964402
Drug: No ocular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No ocular hypotensive agent (control group)
Trial: 16547381
Drug: Indomethacin (INDO)
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin (INDO) 0.2‐0.2‐0.2 mg/kg
Trial: 16547381
Drug: Ibuprofen (IBU)
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen (IBU) 10‐5‐5 mg/kg
Trial: 9359536
Drug: bezafibrate (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bezafibrate (200 mg 3 times daily)
Trial: 8201912
Drug: Voltaren sustained
RxNorm normalized name: Voltarene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voltaren sustained release, 100 mg once a day
Trial: 8201912
Drug: Nodo regular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nodo regular formulation, 200 mg once a day
Trial: 3018564
Drug: 0.5 ml
RxNorm normalized name: ethanol 0.5 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 ml of intramuscular iodized oil
Trial: 20426866
Drug: Maintenance Cognitive
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance Cognitive Stimulation Therapy (CST) for 24 weeks after initial CST for 7 weeks
Trial: 20426866
Drug: Cognitive Stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Stimulation Therapy (CST) for 7 weeks followed by treatment as usual for 24 weeks
Trial: 18617301
Drug: Pentoxifylline (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (400 mg twice daily for eGFR 30 to 60 mL/min/1.73 m² or once daily for eGFR 10 to 29 mL/min/1.73 m²)
Trial: 11921456
Drug: Tobramycin solution
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tobramycin solution for inhalation (TSI) 300 mg b.i.d. for 24 weeks
Trial: 1741572
Drug: Calcium, Parathyroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium, Parathyroid hormone, Osteocalcine
Trial: 1741572
Drug: Treatment duration
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment duration over 3 years
Trial: 30920874
Drug: Platelet-rich plasma
RxNorm normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-rich plasma (PRP) injected on the buccal aspect of supporting teeth
Trial: 21098317
Drug: Ferric gluconate
RxNorm normalized name: Ferric Gluconate
DrugBank: Ferrous gluconate (DB14488)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferric gluconate 187.5 mg IV every 3 weeks
Trial: 21098317
Drug: Oral daily
RxNorm normalized name: Summer's Eve Sheer Floral Daily Cloths
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral daily ferrous sulfate 325 mg
Trial: 19675481
Drug: Contrast Water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast Water Therapy (C(T)WT)
Trial: 15017207
Drug: Sextant biopsies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sextant biopsies recommended when total PSA was 3 ng/ml or greater at screening rounds 1 and 2, and 2.54 ng/ml or greater at subsequent screening rounds.
Trial: 9487256
Drug: Cyclical etidronate
RxNorm normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cyclical etidronate treatment
Trial: 7961544
Drug: Newer antidepressants
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Newer antidepressants (SSRIs, venlafaxine, bupropion)
Trial: 7961544
Drug: Older tricyclic
RxNorm normalized name: TRICYCLIC ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Older tricyclic antidepressants
Trial: 31009695
Drug: Oxygen therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen therapy targeting an SpO2 of 90–94% (intervention)
Trial: 31009695
Drug: Oxygen therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen therapy targeting an SpO2 of 98–100% (control)
Trial: 29325319
Drug: Half-dose spectral
RxNorm normalized name: Sentinel Spectrum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-dose spectral CT based on GSI Assist with 50% ASIR (group A)
Trial: 29325319
Drug: Half-dose spectral
RxNorm normalized name: Sentinel Spectrum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-dose spectral CT (group A)
Trial: 25410205
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of Peru-15 pCTB vaccine at dosages of 1 ×10(7), 1 ×10(8), 1 ×10(9), and 1 ×10(10) CFU